Decoy Therapeutics Posts $3.53/Share Loss, Missing $2.59 Estimate
DCOY sits 17% above its 52-week low of $0.9.
Summary
Decoy Therapeutics reported a quarterly adjusted loss of $3.53 per share for the quarter ended September 30, well wider than the single analyst's $2.59 loss estimate. Revenue came in at $307.00 thousand and the net loss was $2.99 million. The miss lands alongside the 10-Q filed today, which disclosed a $7.59 million nine-month net loss, $8.17 million of cash with about $2.5 million restricted, and a going-concern warning. The stock has already fallen 44.7% this quarter and 86.0% year to date, so the wider-than-expected loss reinforces an already weak setup rather than surprising on cash alone. The lone analyst still carries a strong buy with a $3.00 median price target, roughly 64.8% above the last close of $1.06 — a gap that now looks harder to justify.
At the time of this announcement, DCOY was trading at $1.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.90 to $20.76. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.